Home Neoplasma 2015 Neoplasma Vol.62, No.4, p.574-581, 2015

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.62, No.4, p.574-581, 2015

Title: Effect of TNFRSF6B neutralization antibody on cell growth suppression and apoptosis induction in glioma cells
Author: Y. RUAN, S. HUANG, D. HE, R. GOPAUL, Z. LI, G. CHEN

Abstract: Previously, we have reported that tumor necrosis factor receptor super-family member 6b (TNFRSF6B) is overexpressed in glioma tissues, as well as in the supernatant of cultured glioma cells. However, the function of TNFRSF6B in glioma remains unclarified. The aim of the study was to investigate the effect of anti-TNFRSF6B neutralization monoclonal antibody on the malignant phenotype of glioma cells in vitro. Three glioma cell lines U251MG, LN-308 and U87MG were treated with anti-TNFRSF6B antibody. Cell growth, cell cycle, apoptosis and relevant downstream signaling were detected further. We found that anti-TNFRSF6B antibody inhibited cell growth and induced apoptosis in time and dose-dependent manners in the glioma cells tested. Cell cycle was also arrested in G1/S-phase. Furthermore, anti-TNFRSF6B antibody downregulated the level of MMP-2, phospho-ERK1/2 and phospho-AKT. In conclusion, anti-TNFRSF6B treatment might be a critical targeted therapy strategy for gliomas due to its contribution to suppress cell growth and induce apoptosis.

Keywords: TNFRSF6B, glioma, proliferation, apoptosis, neutralization antibody
Published online: 18-May-2015
Year: 2015, Volume: 62, Issue: 4 Page From: 574, Page To: 581
doi:10.4149/neo_2015_069


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.